Citing disappointing data from the Phase 3 MERU study that failed to show a survival benefit in a first-line setting, AbbVie (NYSE:ABBV) has terminated development of antibody-drug conjugate (ADC) Rovalpituzumab Tesirine (Rova-T) for the maintenance treatment of advanced small-cell lung cancer (SCLC) .
Results will be submitted for presentation at a future medical conference.
In December 2018, it stopped enrollment in another Phase 3, TAHOE, in second-line SCLC due to the absence of a survival benefit compared to topotecan.
The company secured the rights to Rova-T via its 2016 acquisition of Stemcentrx for $5.8B in cash and stock.
Shares are up 1% premarket on light volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.